Compare FDC LTD. with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FDC LTD. vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FDC LTD. PANACEA BIOTECH FDC LTD./
PANACEA BIOTECH
 
P/E (TTM) x 17.5 12.2 143.3% View Chart
P/BV x 2.4 2.9 80.7% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FDC LTD.   PANACEA BIOTECH
EQUITY SHARE DATA
    FDC LTD.
Mar-18
PANACEA BIOTECH
Mar-18
FDC LTD./
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs319364 87.6%   
Low Rs164129 127.0%   
Sales per share (Unadj.) Rs61.696.8 63.7%  
Earnings per share (Unadj.) Rs9.9-12.4 -80.2%  
Cash flow per share (Unadj.) Rs12.0-2.9 -419.5%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs73.250.4 145.2%  
Shares outstanding (eoy) m174.4061.25 284.7%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.92.5 153.8%   
Avg P/E ratio x24.3-19.9 -122.2%  
P/CF ratio (eoy) x20.2-86.4 -23.4%  
Price / Book Value ratio x3.34.9 67.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m42,11815,101 278.9%   
No. of employees `0005.52.5 224.1%   
Total wages/salary Rs m2,1671,516 142.9%   
Avg. sales/employee Rs Th1,943.72,401.9 80.9%   
Avg. wages/employee Rs Th391.7614.2 63.8%   
Avg. net profit/employee Rs Th313.7-307.9 -101.9%   
INCOME DATA
Net Sales Rs m10,7515,928 181.4%  
Other income Rs m51082 619.2%   
Total revenues Rs m11,2606,010 187.4%   
Gross profit Rs m2,267845 268.2%  
Depreciation Rs m351585 60.0%   
Interest Rs m141,006 1.4%   
Profit before tax Rs m2,411-664 -363.4%   
Minority Interest Rs m-50-   
Prior Period Items Rs m02 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m67199 680.7%   
Profit after tax Rs m1,735-760 -228.3%  
Gross profit margin %21.114.3 147.9%  
Effective tax rate %27.8-14.9 -187.3%   
Net profit margin %16.1-12.8 -125.9%  
BALANCE SHEET DATA
Current assets Rs m7,2135,603 128.7%   
Current liabilities Rs m2,1046,910 30.4%   
Net working cap to sales %47.5-22.0 -215.6%  
Current ratio x3.40.8 422.8%  
Inventory Days Days54206 26.5%  
Debtors Days Days2884 33.1%  
Net fixed assets Rs m6,8659,941 69.1%   
Share capital Rs m17561 285.8%   
"Free" reserves Rs m12,5863,026 416.0%   
Net worth Rs m12,7613,087 413.4%   
Long term debt Rs m65,707 0.1%   
Total assets Rs m15,04116,076 93.6%  
Interest coverage x173.20.3 50,898.7%   
Debt to equity ratio x01.8 0.0%  
Sales to assets ratio x0.70.4 193.8%   
Return on assets %11.61.5 760.5%  
Return on equity %13.6-24.6 -55.2%  
Return on capital %19.03.9 484.1%  
Exports to sales %12.324.0 51.4%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs m1,3271,424 93.2%   
Imports (cif) Rs mNA1,040 0.0%   
Fx inflow Rs m1,8891,600 118.1%   
Fx outflow Rs m01,131 0.0%   
Net fx Rs m1,889469 403.1%   
CASH FLOW
From Operations Rs m1,4981,180 127.0%  
From Investments Rs m201553 36.4%  
From Financial Activity Rs m-1,694-1,644 103.1%  
Net Cashflow Rs m1090 11.5%  

Share Holding

Indian Promoters % 68.9 74.5 92.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.7 0.6 783.3%  
FIIs % 7.5 1.3 576.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.0 23.6 80.5%  
Shareholders   23,730 10,259 231.3%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FDC LTD. With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  WOCKHARDT  SUN PHARMA  

Compare FDC LTD. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

FDC LTD. Announces Quarterly Results (1QFY20); Net Profit Up 2.4% (Quarterly Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

For the quarter ended June 2019, FDC LTD. has posted a net profit of Rs 523 m (up 2.4% YoY). Sales on the other hand came in at Rs 3 bn (up 17.9% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

FDC LTD. Announces Quarterly Results (4QFY19); Net Profit Up 6.8% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, FDC LTD. has posted a net profit of Rs 337 m (up 6.8% YoY). Sales on the other hand came in at Rs 3 bn (down 0.6% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

FDC LTD. 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of FDC LTD. for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of FDC LTD.. Also includes updates on the valuation of FDC LTD..

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FDC LTD. SHARE PRICE


Sep 20, 2019 (Close)

TRACK FDC LTD.

  • Track your investment in FDC LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FDC LTD. - GLENMARK PHARMA COMPARISON

COMPARE FDC LTD. WITH

MARKET STATS